AOD-9604
AOD-9604 is formulated to help accelerate fat metabolism, support weight management, and promote a leaner body composition without affecting blood sugar or growth hormone levels.
Promotes targeted fat loss
Boosts metabolism and energy levels
Helps preserve lean muscle during weight loss
Non-hormonal and non-stimulant
* Price reflects a 6-month treatment plan
AOD-9604 is a modified fragment of human growth hormone (HGH) that specifically targets the fat-burning region of the molecule. It stimulates lipolysis (the breakdown of stored fat) while inhibiting lipogenesis (the formation of new fat), helping the body use fat for energy more efficiently. Unlike traditional HGH, it does not raise IGF-1 or blood glucose levels, making it a safer, targeted approach for fat loss.
Developed in the 1990s by Metabolic Pharmaceuticals in Australia, AOD-9604 was designed to isolate HGH’s fat-metabolizing properties without its growth-stimulating effects. Preclinical and human studies have demonstrated its ability to increase fat oxidation, reduce adipose tissue mass, and improve lipid profiles. Trials have also indicated that AOD-9604 is well-tolerated, with no significant impact on insulin sensitivity or blood sugar control. Continued research supports its potential as a novel therapeutic for weight management and metabolic support.
AOD-9604 is generally well-tolerated, with rare reports of mild injection-site irritation, headache, or transient fatigue. As with all peptide therapies, it should be used under professional guidance to ensure safe and effective dosing.
See the Science
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,2013
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health2014
Effects of Human GH and Its Lipolytic Fragment (AOD-9604) on Reduction of Body Fat in Obese Mice2001
Metabolic Studies of a Synthetic Lipolytic Domain (AOD-9604) of Human Growth Hormone in Obese Zucker Rats2000
Key Takeaways
Targets Fat Metabolism
Non-Hormonal & Non-Stimulant
Focused on Body Composition
Clinically Well-Tolerated
Frequently asked questions
AOD-9604 has not been approved by the U.S. Food and Drug Administration. It can only be prescribed through licensed clinicians where state law allows.
Yes, multiple human trials show good safety and tolerability, with studies suggesting modest body-fat reduction and improved lipid metabolism.
AOD-9604 seems to help stimulate the breakdown of stored fat (lipolysis) and prevent new fat formation (anti-lipogenesis). It’s used to support metabolic health and weight-management programs by enhancing fat oxidation and energy efficiency.
Clinical data show AOD-9604 is well tolerated with no effect on blood sugar or growth hormone levels. The most common side effect is mild injection-site irritation.
Individuals who are pregnant, nursing, or managing metabolic, endocrine, or cancer-related conditions should avoid AOD-9604 unless prescribed and monitored by a clinician.
AOD-9604 is administered via subcutaneous injection, typically in the abdomen.
AOD-9604 is sometimes combined with CJC-1295 + Ipamorelin for synergistic fat-loss support, or MOTS-C for enhanced metabolic efficiency. Any stack should be clinician-supervised.
How AIRA works
Medical Intake
Prescription
Delivery
Why AIRA?
Your body already holds the blueprint — AIRA helps you unlock it. Our physician-guided peptide programs will help you perform, recover, and feel your best.
Chat with a provider 24/7
Trusted pharmacy
Manage goals in one place
Fast, discreet shipping
Start your new AIRA today
Unleash a healthier, more energetic version of yourself with AIRA. Check out treatments now and embark on your journey to a fulfilling life.
